Revenue: As of FY2026 Q1, the actual value is USD 0.EPS: As of FY2026 Q1, the actual value is USD -4.35.EBIT: As of FY2026 Q1, the actual value is USD -8.371 M.<h3>Segment Revenue and Operational Metrics</h3><ul><li>Research and Development Expenses: For the three-month period ended October 31, 2025, research and development expenses were $6,683,643, compared to $3,665,341 for the same period in 2024. This increase was primarily due to higher clinical trial sites and investigational drug costs, which rose from $2,439,667 in 2024 to $4,863,199 in 2025.</li><li>General and Administrative Expenses: For the three-month period ended October 31, 2025, general and administrative expenses were $1,639,300, compared to $1,487,491 for the same period in 2024. The increase was driven primarily by higher shareholder communications costs and increased wages and salaries.</li><li>Operating Loss: The operating loss for the three-month period ended October 31, 2025, was $8,322,943, compared to $5,152,832 for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: For the period ended October 31, 2025, net cash used in operating activities was $7,704,796, compared to $6,955,076 for the period ended October 31, 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Net Loss: The net loss for the three-month period ended October 31, 2025, was $8,278,328, compared to $5,829,276 for the same period in 2024. The higher loss primarily reflects increased research and development spending.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company is advancing its Bria-IMT™ targeted immunotherapy in a pivotal Phase 3 study in metastatic breast cancer, with plans to present positive biomarker data and top-line data expected as early as the first half of 2026.</li><li>Non-Core Business: The company is developing Bria-OTS™ and its advanced form, Bria-OTS+™, as a platform technology for personalized off-the-shelf immunotherapies for numerous types of cancer, with ongoing preclinical and clinical development activities.</li></ul>

BRIACELL THERAPEUTICS CORP C/WTS 26/02/2026(TO PUR COM) | 10-Q: FY2026 Q1 Revenue: USD 0